Clinical outcomes following hematopoietic stem cell transplantation for the treatment of mucopolysaccharidosis VI

Molecular Genetics and Metabolism

Volumn 102, Issue 2, 2011, Pages 111-115

  Turbeville, Sean ^a   Nicely, Helen ^a   Rizzo, J Douglas ^b   Pedersen, Tanya L ^c   Orchard, Paul J ^d   Horwitz, Mitchell E ^e   Horwitz, Edwin M ^f   Veys, Paul ^g   Bonfim, Carmem ^h   Al Seraihy, Amal ⁱ  

^a BIOMARIN PHARMACEUTICAL INC   (United States)

^b MEDICAL COLLEGE OF WISCONSIN   (United States)

^c CENTER FOR INTERNATIONAL BLOOD AND MARROW TRANSPLANT RESEARCH   (United States)

^d UNIVERSITY OF MINNESOTA   (United States)

^e DUKE UNIVERSITY MEDICAL CENTER   (United States)

^f 6 Penn Tower   (United States)

^g Great Ormond Street Hospital for Children NHS Trust   (United Kingdom)

^h FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

ⁱ KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

Author keywords

Arylsulfatase B; Enzyme replacement therapy; Galsulfase; Hematopoietic stem cell transplantation; Mortality; Mucopolysaccharidosis VI

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE;

ACUTE GRAFT VERSUS HOST DISEASE; ADOLESCENT; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CHILD; CLINICAL ARTICLE; ENZYME REPLACEMENT; FEMALE; GRAFT RECIPIENT; HUMAN; INCIDENCE; INFORMATION PROCESSING; MALE; MAROTEAUX LAMY SYNDROME; OUTCOME ASSESSMENT; POSTOPERATIVE PERIOD; PRESCHOOL CHILD; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK BENEFIT ANALYSIS; SCHOOL CHILD; SURVIVAL RATE; TREATMENT OUTCOME;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INCIDENCE; INFANT; MALE; MUCOPOLYSACCHARIDOSIS VI; NEUTROPHILS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 78651426962     PISSN: 10967192     EISSN: 10967206     Source Type: Journal    
DOI: 10.1016/j.ymgme.2010.09.010     Document Type: Article

References (34)

1. Litjens T., Baker E., Beckmann K., Morris C., Hopwood J., Callen D. Chromosomal localization of ARSB, the gene for human N-acetylgalactosamine-4-sulphatase. Hum. Genet. 1989, 82:67-68.
2. Neufeld E., Muenzer J. The mucopolysaccharidoses. The Metabolic and Molecular Bases of Inherited Disease 2001, 3421-3452. McGraw-Hill, New York, NY. C. Scriver, A. Beaudet, W. Sly, D. Valle (Eds.).
3. Staretz-Chacham O., Lang T., LaMarca M., Krasnewich D., Sidransky E. Lysosomal storage disorders in the newborn. Pediatrics 2009, 123:1191-1207.
4. Baehner F., Schmiedeskamp C., Krummenauer F., Miebach E., Bajbouj M., Whybra C., Kohlschutter A., Kampmann C., Beck M. Cumulative incidence rates of the mucopolysaccharidoses in Germany. J. Inherit. Metab. Dis. 2005, 28:1011-1017.
5. Malm G., Lund A., Mansson J., Heiberg A. Mucopolysaccharidoses in the Scandinavian countries: incidence and prevalence. Acta Paediatr. 2008, 97:1577-1581.
6. Swiedler S., Beck M., Bajbouj M., Giugliani R., Schwartz I., Harmatz P., Wraith J., Roberts J., Ketteridge D., Hopwood J., Guffon N., Sá Miranda M., Teles E., Berger K., Piscia-Nichols C. Threshold effect of urinary glycosaminoglycans and the walk test as indicators of disease progression in a survey of subjects with mucopolysaccharidosis VI (Maroteaux-Lamy syndrome). Am. J. Med. Genet. 2005, 134:144-150.
7. Valayannopoulos V., Nicely H., Harmatz P., Turbeville S. Mucopolysaccharidosis VI. Orphanet J. Rare Dis. 2010, 5:1-20.
8. Meikle P., Hopwood J. Lysosomal storage disorders: emerging therapeutic options require early diagnosis. Eur. J. Pediatr. 2003, 162:S34-S37.
9. Wenger D., Coppola S., Liu S. Insights into the diagnosis and treatment of lysosomal storage diseases. Arch. Neurol. 2003, 60:322-328.
10. Giugliani R., Harmatz P., Wraith J. Management guidelines for mucopolysaccharidosis VI. Pediatrics 2007, 120:405-418.
11. BioMarin Pharmaceutical Naglazyme® (galsulfase) Solution for Intravenous Infusion Prescribing Information 2005.
12. Boelens J., Wynn R., O'Meara A., Veys P., Bertrand Y., Souillet G., Wraith J., Fischer A., Cavazzana-Calvo M., Sykora K., Sedlacek P., Rovelli A., Uiterwaal C., Wulffraat N. Outcomes of hematopoietic stem cell transplantation for Hurler's syndrome in Europe: a risk factor analysis for graft failure. Bone Marrow Transplant. 2007, 40:225-233.
13. del Pozo J. Update and actual trends on bacterial infections following liver transplantation. World J. Gastroenterol. 2008, 14:4977-4983.
14. Staba S., Escolar M., Poe M., Kim Y., Martin P., Szabolcs P., Allison-Thacker J., Wood S., Wenger D., Rubinstein P., Hopwood J., Krivit W., Kurtzberg J. Cord-blood transplants from unrelated donors in patients with Hurler's syndrome. N Engl J. Med. 2004, 350:1960-1969.
15. Pastores G., Arn P., Beck M., Clarke J., Guffon N., Kaplan P., Muenzer J., Norato D., Shapiro E., Thomas J., Viskochil D., Wraith J. The MPS I registry: design, methodology, and early findings of a global disease registry for monitoring patients with mucopolysaccharidosis type I. Mol. Genet. Metab. 2007, 91:37-47.
16. Boelens J., Rocha V., Aldenhoven M., Wynn R., O'Meara A., Michel G., Ionescu I., Parikh S., Prasad V., Szabolcs P., Escolar M., Gluckman E., Cavazzana-Calvo M., Kurtzberg J. Risk factor analysis of outcomes after unrelated cord blood transplantation in patients with Hurler syndrome. Biol. Blood Marrow Transplant. 2009, 15:618-625.
17. Tolar J., Grewal S., Bjoraker K., Whitley C., Shapiro E., Charnas L., Orchard P. Combination of enzyme replacement and hematopoietic stem cell transplantation as therapy for Hurler syndrome. Bone Marrow Transplant. 2008, 41:531-535.
18. Wynn R., Wraith J., Mercer J., O'Meara A., Tylee K., Thornley M., Church H., Bigger B. Improved metabolic correction in patients with lysosomal storage disease treated with hematopoietic stem cell transplant compared with enzyme replacement therapy. J. Pediatr. 2009, 154:609-611.
19. Krivit W., Pierpont M., Ayaz K., Tsai M., Ramsay N., Kersey J., Weisdorf S., Sibley R., Snover D., McGovern M. Bone-marrow transplantation in the Maroteaux-Lamy syndrome (mucopolysaccharidosis type VI). Biochemical and clinical status 24months after transplantation. N Engl J. Med. 1984, 311:1606-1611.
20. Krivit W. Allogeneic stem cell transplantation for the treatment of lysosomal and peroxisomal metabolic diseases. Springer Semin. Immunopathol. 2004, 26:119-132.
21. Wang C., Hwu W., Lin K. Long-term follow-up of a girl with Maroteaux-Lamy syndrome after bone marrow transplantation. World J. Pediatr. 2008, 4:152-154.
22. Przepiorka D., Weisdorf D., Martin P., Klingemann H., Beatty P., Hows J., Thomas E. Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant. 1995, 15:825-828.
23. Filipovich A., Weisdorf D., Pavletic S., Socie G., Wingard J., Lee S., Martin P., Chien J., Przepiorka D., Couriel D., Cowen E., Dinndorf P., Farrell A., Hartzman R., Henslee-Downey J., Jacobsohn D., McDonald G., Mittleman B., Rizzo J., Robinson M., Schubert M., Schultz K., Shulman H., Turner M., Vogelsang G., Flowers M. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol. Blood Marrow Transplant. 2005, 11:945-956.
24. Klein J., Moeschberger M. Survival Analysis: Techniques of Censored and Truncated Data 2003, Springer-Verlag.
25. Scarpa M., Fiumara B.R.A., Astarita L., Parenti G., Rampazzo A., Sala S., Sorge G., Parini R. Mucopolysaccharidosis VI: the Italian experience. Eur. J. Pediatr. 2009, 168:1203-1206.
26. Herskhovitz E., Young E., Rainer J., Hall C., Lidchi V., Chong K., Vellodi A. Bone marrow transplantation for Maroteaux-Lamy syndrome (MPS VI): long-term follow-up. J. Inherit. Metab. Dis. 1999, 22:50-62.
27. Malatack J., Consolini D., Bayever E. The status of hematopoietic stem cell transplantation in lysosomal storage disease. Pediatr. Neurol. 2003, 29:391-403.
28. Beck M. New therapeutic options for lysosomal storage disorders: enzyme replacement, small molecules and gene therapy. Hum. Genet. 2007, 121:1-22.
29. Boelens J. Trends in haematopoietic cell transplantation for inborn errors of metabolism. J. Inherit. Metab. Dis. 2006, 29:413-420.
30. Orchard P., Blazar B., Wagner J., Charnas L., Krivit W., Tolar J. Hematopoietic cell therapy for metabolic disease. J. Pediatr. 2007, 151:340-346.
31. Rovelli A. The controversial and changing role of haematopoietic cell transplantation for lysosomal storage disorders: an update. Bone Marrow Transplant. 2008, 41:S87-S89.
32. Prasad V., Kurtzberg J. Transplant outcomes in mucopolysaccharidoses. Semin. Hematol. 2010, 47:59-69.
33. Peters C., Balthazor M., Shapiro E., King R., Kollman C., Hegland J., Henslee-Downey J., Trigg M., Cowan M., Sanders J., Bunin N., Weinstein H., Lenarsky C., Falk P., Harris R., Bowen T., Williams T., Grayson G., Warkentin P., Sender L., Cool V., Crittenden M., Packman S., Kaplan P., Lockman L., Anderson J., Krivit W., Dusenbery K., Wagner J. Outcome of unrelated donor bone marrow transplantation in 40 children with Hurler syndrome. Blood 1996, 87:4894-4902.
34. Grewal S., Wynn R., Abdenur J., Burton B., Gharib M., Haase C., Hayashi R., Shenoy S., Sillence D., Tiller G., Dudek M., van Royen-Kerkhof A., Wraith J., Woodard P., Young G., Wulffraat N., Whitley C., Peters C. Safety and efficacy of enzyme replacement therapy in combination with hematopoietic stem cell transplantation in Hurler syndrome. Genet. Med. 2005, 7:143-146.